RxDoctor Payments Data

Benjamin Goins, DO

Cardiovascular Disease · Eglin Afb, FLNPI 1144514753

Payments from drug & device makers

$13,140in general payments, 2019–2025

Across 131 payments — averaging $100.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$11K
  • Amgen$287
  • Merck$251
  • Novartis$241
  • E.r. Squibb & Sons, L.L.C.$192
  • Pfizer$155
  • plus $961 from 20 others

What the payments were for

  • Speaking & faculty fees$10,34679%
  • Food & beverage$2,68820%
  • Education$1061%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,140 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$222,102
Medicare patients
839
Services billed
2,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban211$207,122
XareltoRivaroxaban86$69,806
OzempicSemaglutide54$60,293
JardianceEmpagliflozin39$53,265
MounjaroTirzepatide38$43,899
EntrestoSacubitril/Valsartan24$25,073
FarxigaDapagliflozin Propanediol12$13,585
BrilintaTicagrelor13$9,204
Ezetimibe161$4,671
Nifedipine ErNifedipine124$3,274
Eplerenone43$2,679
Nebivolol Hcl61$2,475
Rosuvastatin Calcium254$2,085
Valsartan84$2,035
Carvedilol202$1,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$155$207,122211 claims
Johnson & JohnsonXarelto$64$69,80686 claims
Novo NordiskOzempic$11,054$60,29354 claims
Boehringer IngelheimJardiance$41$53,26539 claims
NovartisEntresto$241$25,07324 claims
AstraZenecaFarxiga, Brilinta$80$22,78925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Eglin Afb

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →